{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'APPENDIX A', 'CLINICAL LABORATORIES (Amended 19', 'October 2018)', 'Table 14', \"GSK Biologicals' laboratories\", 'Laboratory', 'Address', 'GSK Biologicals Clinical', 'Biospecimen Reception - B7/44', 'Laboratory Sciences (CLS)', \"Rue de l'Institut, 89 - B-1330 Rixensart -\", 'Rixensart', 'Belgium', 'GSK Biologicals Clinical', 'Avenue Fleming, 20 - B-1300 Wavre - Belgium', 'Laboratory Sciences (CLS)', 'Wavre-Nord Noir Epine', 'Table 15', 'Outsourced Laboratories', 'Laboratory', 'Address', 'Q\u00b2 Solutions Clinical Trials (US)', '27027 Tourney Road, Suite 2E', 'Valencia, CA 91355', 'USA', 'Q\u00b2 Solutions (Singapore)', 'Tan Tock Seng Hospital', 'Dept of Laboratory Medicine', 'Level 2, Podium Block', 'Tan Tock Seng Hospital', '11 Jalan Tan Tock Seng', 'Singapore 308433', 'DDL Diagnostic Laboratory B.V.', 'Fonteijnenburghlaan 7', 'Voorburg', 'Netherland', '19-OCT-2018', '78', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'APPENDIX B', 'AMENDMENT TO THE PROTOCOL', 'GlaxoSmithKline Biologicals', 'Vaccine Value & Health Science (VVHS)', 'Protocol Amendment 1', 'eTrack study number', '201112 (EPI-NTHI-001 BOD APA)', 'and Abbreviated Title', 'Amendment number:', 'Amendment 1', 'Amendment date:', '13 February 2017', 'PPD', 'Co-ordinating author:', 'Scientific Writer', 'Rationale/background for changes:', 'The protocol amendment has been issued to implement the following changes:', 'Alignment of the protocol to the updated GOLD consensus report of 2017 and the', 'COPD fact sheet.', 'Alignment of the study endpoints to the study objectives.', 'Overall update based on the scientific and operational experience gained from the', 'current COPD studies.', 'To update the new literature references.', 'To reflect the upgrade to new version for CRF, ICF, protocol, SPM and overall', 'changes in the functions due to reorganization.', 'To correct some typographical errors.', \"Update of the GSK laboratory's name.\", 'Amended text has been included in bold italics and deleted text in strikethrough in the', 'following sections:', 'Title page:', 'Title', 'Occurrence of potential bacterial and viral pathogens', 'in stable chronic obstructive pulmonary disease', '(COPD) and during acute exacerbations of COPD', '(AECOPD), in Asia Pacific.', '19-OCT-2018', '79', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Contributing authors', 'PPD', 'Epidemiologist', 'PPD', 'Clinical Research', 'Development and Research Development Lead', 'PPD', 'Clinical', 'Research-Development and Research', 'Development Lead', 'PPD', 'Biostatistician', 'PPD', 'Lead', 'statistician', 'PPD', 'Project', 'Delivery Lead', 'PPD', 'Study Delivery Lead', 'PPD', 'Study Delivery Manager,', '(External Consultant [Freelance]for GSK', 'Biologicals)', 'PPD', 'Study Data', 'Manager (Business & Decision Life Sciences for', 'GSK Biologicals) Senior Manager, Oversight', 'Data Management', 'PPD', 'Study Data Manager', 'PPD', 'Vaccine Supply', 'Coordinator (CVO Europe, for GSK Biologicals)', 'PPD', 'Project Manager, GVCL', 'Clinical Readout Team Leader, Clinical', 'Laboratory Sciences', 'PPD', 'Study Manager, GVCL', '(Business & Decision Life sciences, for GSK', 'Biologicals)/', 'PPD', 'Study Manager,', 'Clinical Laboratory Sciences', 'PPD', 'Global', 'PPD', 'Regulatory Lead and', 'Technical', 'Global Regulatory Affairs representative', '19-OCT-2018', '80', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']\n\n###\n\n", "completion": "END"}